

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Rachael ANCLIFF et al.

Conf. No. 5647

Serial No.: 10/531,758

Art Unit: 1624

Filing Date: April 14, 2005

Examiner: Coleman, Brenda Libby

For: Substituted Piperazines, (1,4) Diazepines, and 2,5-Diazabicyclo (2.2.1) Heptaines as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☐ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_.  
(37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No. 07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
James P. Riek  
Attorney of Record  
Registration No. 39,009

Date: November 15, 2006  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8022  
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT						SERIAL NO.	10/531,758	
						FILING DATE	April 14, 2005	
						APPLICANT	Rachael Ancliff et al.	
						GROUP	1624	
						EXAMINER	Coleman, Brenda Libby	
						ATTORNEY DOCKET NO.	P33126USw	
U.S. PATENT DOCUMENTS								
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
Continue on page _____								
FOREIGN PATENT DOCUMENTS								
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No	
Continue on page _____								
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)								
	1.	Co-pending U.S. Application No. 11/112,048, filed April 22, 2005						
Continue on page _____								
EXAMINER						DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								